Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

Research output: Contribution to journal › Comment/debate › Research › peer-review

Standard

Correction to : Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). / The VISIONARY Study Group.

In: Advances in Therapy, Vol. 39, No. 8, 2022, p. 3522-3523.

Research output: Contribution to journal › Comment/debate › Research › peer-review

Harvard

The VISIONARY Study Group 2022, 'Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)', Advances in Therapy, vol. 39, no. 8, pp. 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

APA

The VISIONARY Study Group (2022). Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy, 39(8), 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

Vancouver

The VISIONARY Study Group. Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy. 2022;39(8):3522-3523. https://doi.org/10.1007/s12325-022-02210-5

Author

The VISIONARY Study Group. / Correction to : Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). In: Advances in Therapy. 2022 ; Vol. 39, No. 8. pp. 3522-3523.

Bibtex

@article{d2d6dbe55f744f9aa336dea0623537e9,
title = "Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)",
abstract = "The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected. ",
author = "Francesco Oddone and James Kirwan and Fernando Lopez-Lopez and Marina Zimina and Claudia Fassari and G{\'a}bor Holl{\'o} and Christoph Faschinger and Enping Chen and Gabor Nemeth and Gyorgy Bator and Alexis Tsorbatzoglou and Tamas Acs and Maria Ferencz and Zolt{\'a}n Sohajda and Jeno Toth and Veronika Volner and G{\'a}bor Vogt and Zsolt Biro and Andrea Facsk{\'o} and J{\'a}nos Nemes and Andras Berta and Ilona Elek and Eugene Ng and Francesco Oddone and Gemma Rossi and Luca Rossetti and Michele Vetrugno and Michele Iester and Giorgio Marchini and Vincenzo Scorcia and Giovanni Staurenghi and Carlo Cagini and Tommaso Salgarello and Paolo Bettin and Michele Figus and Scuderi, {Gian Luca} and {De Cilla}, Stefano and Iveta Grundmane and Nora Linavska and Lasma Volksone and Guna Laganovska and Kristine Baumane and Hans Lemij and Gundersen, {Kjell Gunnar} and Valery Erichev and Elmira Adbulaeva and Elena Karlova and Ekaterina Zakharova and Irina Panova and Miriam Kolko and {The VISIONARY Study Group}",
note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2022.",
year = "2022",
doi = "10.1007/s12325-022-02210-5",
language = "English",
volume = "39",
pages = "3522--3523",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Adis International Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Correction to

T2 - Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

AU - Oddone, Francesco

AU - Kirwan, James

AU - Lopez-Lopez, Fernando

AU - Zimina, Marina

AU - Fassari, Claudia

AU - Holló, Gábor

AU - Faschinger, Christoph

AU - Chen, Enping

AU - Nemeth, Gabor

AU - Bator, Gyorgy

AU - Tsorbatzoglou, Alexis

AU - Acs, Tamas

AU - Ferencz, Maria

AU - Sohajda, Zoltán

AU - Toth, Jeno

AU - Volner, Veronika

AU - Vogt, Gábor

AU - Biro, Zsolt

AU - Facskó, Andrea

AU - Nemes, János

AU - Berta, Andras

AU - Elek, Ilona

AU - Ng, Eugene

AU - Oddone, Francesco

AU - Rossi, Gemma

AU - Rossetti, Luca

AU - Vetrugno, Michele

AU - Iester, Michele

AU - Marchini, Giorgio

AU - Scorcia, Vincenzo

AU - Staurenghi, Giovanni

AU - Cagini, Carlo

AU - Salgarello, Tommaso

AU - Bettin, Paolo

AU - Figus, Michele

AU - Scuderi, Gian Luca

AU - De Cilla, Stefano

AU - Grundmane, Iveta

AU - Linavska, Nora

AU - Volksone, Lasma

AU - Laganovska, Guna

AU - Baumane, Kristine

AU - Lemij, Hans

AU - Gundersen, Kjell Gunnar

AU - Erichev, Valery

AU - Adbulaeva, Elmira

AU - Karlova, Elena

AU - Zakharova, Ekaterina

AU - Panova, Irina

AU - Kolko, Miriam

AU - The VISIONARY Study Group

N1 - Publisher Copyright: © Springer Healthcare Ltd., part of Springer Nature 2022.

PY - 2022

Y1 - 2022

N2 - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

AB - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

U2 - 10.1007/s12325-022-02210-5

DO - 10.1007/s12325-022-02210-5

M3 - Comment/debate

C2 - 35731341

AN - SCOPUS:85133655439

VL - 39

SP - 3522

EP - 3523

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 8

ER -

ID: 327065633